Goldman Sachs Starts Surface Oncology (SURF) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
Evercore ISI Starts Surface Oncology (SURF) at Outperform
May 14, 2018 6:04 AM EDTEvercore ISI initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating and a price target of $26.00.
Analyst Josh Schimmer said they believe SURF's approach of targeting the innate immune system as well is differentiated, and the company is developing a portfolio of... More
Cowen Starts Surface Oncology (SURF) at Outperform
May 14, 2018 5:38 AM EDTCowen initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating.
Analyst Boris Peaker comments "Surface is developing several drugs against novel IO targets. Given the early stage nature of these targets, we believe that positive developments internally as well as... More
